Key Takeaways
- Selank is a synthetic heptapeptide analog of tuftsin developed at the Institute of Molecular Genetics, Russian Academy of Sciences.
- The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, pairing the tuftsin tetrapeptide with a stabilizing Pro-Gly-Pro C-terminal segment.
- Published work examines GABA-A receptor allosteric modulation, BDNF-related gene expression, enkephalin turnover, and CNS model-system endpoints.
- The literature also includes host-defense signaling, peptide stability, and functional-connectivity model data.
- For RUO settings, the compound is best framed as a pathway-research material, not as a consumer wellness or clinical product.
Introduction
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic tuftsin analog used in laboratory literature on CNS signaling and peptide biology. It was developed through work associated with the Institute of Molecular Genetics, Russian Academy of Sciences, and appears in studies involving GABAergic pathways, neurotrophin-related gene expression, and peptide-stability questions.
This overview summarizes the published research in neutral RUO terms. The focus is on molecular targets, model systems, and experimental endpoints rather than consumer outcomes or clinical claims.
Chemical Structure and Design
Selank extends the naturally occurring tuftsin tetrapeptide sequence, Thr-Lys-Pro-Arg, with the C-terminal tripeptide Pro-Gly-Pro. That added segment is discussed in the literature as a stability-oriented modification that changes peptide persistence compared with the shorter parent sequence.
The Pro-Gly-Pro region is commonly described in relation to peptidase resistance, central-compartment distribution in model systems, and longer observation windows for laboratory protocols. These structural features are part of why Selank is used as a comparative material in peptide-pathway research.
Mechanism-of-Action Literature
GABA-A Receptor Modulation
A 2018 paper reported subtype-selective, concentration-dependent allosteric modulation of GABA-A receptors by Selank [1]. In RUO language, this positions the compound as a material for studying receptor-subtype behavior and allosteric signaling.
The same body of work is often compared with benzodiazepine-class receptor modulation, but a compliance-safe description should keep the comparison at the pathway level: receptor site, receptor subtype, ligand response, and assay endpoint.
BDNF-Related Gene Expression
Published work in Frontiers in Pharmacology examined Selank alongside GABA and olanzapine in gene-expression models connected with GABAergic neurotransmission [2]. Other model-system work discusses BDNF-linked transcriptional changes in brain-region samples.
For storefront and article copy, BDNF should be framed as a molecular marker and pathway variable. Claims about improvement, protection, treatment, or human benefit should be avoided.
Enkephalin Turnover
Selank has also been studied in connection with endogenous enkephalin turnover and enzyme-mediated peptide degradation [3]. This area is useful for research into peptide persistence, cleavage pathways, and downstream signaling markers.
Model-System Findings
Behavioral Assay Endpoints
Several rodent studies examine Selank in standardized behavioral-assay systems, including comparison designs involving diazepam under chronic mild challenge conditions [4]. A neutral summary should describe the work as behavioral endpoint measurement, receptor-pathway comparison, and experimental-condition analysis.
This phrasing preserves the scientific context without presenting Selank as a product for a human state, symptom, or desired outcome.
Memory-Task and Gene-Expression Models
Other studies use memory-task models and brain-region gene-expression measurements to examine how Selank relates to GABAergic signaling and BDNF-associated variables [5]. In RUO materials, these findings are best described by the measured endpoint: task-outcome data in a model system, transcript abundance, brain-region sampling, and pathway mapping.
Host-Defense Signaling Models
Because Selank is derived from tuftsin, some literature also touches host-defense signaling and cytokine-related measurements. This is a laboratory signaling topic and should not be converted into consumer-facing immune, resilience, or wellness claims.
Cellular Stress and Viability Markers
Preclinical papers discuss oxidative-state markers, inflammatory signaling variables, synaptic-plasticity markers, and low-oxygen cell-model conditions. These are model-system endpoints, not promises of biological benefit.
Functional Connectivity Research
A 2020 resting-state fMRI study examined Selank and Semax in relation to whole-brain functional-connectivity patterns [6]. The reported endpoints include amygdala-network and temporal-cortex connectivity variables.
That work can be described as network-level CNS mapping. It should not be translated into emotional, diagnostic, or outcome claims in commerce-facing materials.
Research Applications
Selank is suitable for laboratory questions involving peptide stability, tuftsin-analog design, GABA-A receptor modulation, neurotrophin-related transcription, enkephalin turnover, cytokine-marker context, and CNS network mapping.
Useful study designs may compare Selank with related peptides such as Semax, evaluate assay-specific marker changes, or map receptor and transcript relationships across model systems. The strongest compliance posture is to name the pathway or endpoint, not a human-use purpose.
Quality Considerations for Research
Research-grade Selank should be documented with analytical identity, HPLC purity, mass confirmation where available, endotoxin limits for applicable biological models, heavy-metal review, and lot-specific handling records.
Regulatory Status
Selank is sold by Chameleon Peptides strictly as a research-use-only material. It is not a drug, food, supplement, cosmetic, or consumer wellness product, and it is not offered for human consumption, diagnostic use, or medical application.
Future Research Directions
Future work may continue to examine receptor-subtype mapping, peptide-stability variables, transcriptomic and proteomic datasets, single-cell methods, and computational modeling of peptide-receptor interactions.
These directions keep Selank in its proper research frame: a laboratory compound for investigating defined mechanisms and endpoints.
Conclusion
Selank is a well-documented tuftsin-analog research material with literature spanning GABAergic signaling, BDNF-related gene-expression markers, enkephalin turnover, host-defense signaling context, and CNS functional-connectivity models.
The compliance-safe way to discuss Selank is to keep the language anchored to pathway literature and laboratory endpoints. Human-benefit wording, consumer wellness language, and clinical-use framing should be avoided on an RUO storefront.
References
- PMID 30255741 – GABA-A receptor modulation paper.
- Frontiers in Pharmacology, 2017 – gene-expression study involving GABAergic neurotransmission markers.
- PMID 18454096 – enkephalin-turnover and mechanism paper.
- PMC5322660 – rodent behavioral-assay comparison study.
- PMC4757669 – GABAergic neurotransmission gene-expression paper.
- PMID 32342318 – functional-connectivity study.
RESEARCH USE ONLY DISCLAIMER: This information is provided for research and educational purposes only. Selank is intended solely for laboratory research and is not approved for human consumption, therapeutic use, or any medical application. All research involving Selank should be conducted by qualified researchers in appropriate laboratory settings with proper institutional oversight and safety protocols.